Evidence map›Paper›PMID 39612330›Full record

ArticleScience advances2024

Respiratory delivery of single low-dose nebulized PFCE-C25 NEs for lymphatic transport and durable stimulation of antitumor immunity in lung cancer.

Rong A, Zhaoguo Han, Meifang Zhou, Chaoqun Nie, Mengyuan Zhu, Sijie Cheng, Tianyi Wang, Jing Wang, Zhen Quan, Kaiqi Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rong ADepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0002-6246-4682
Zhaoguo HanDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0003-2895-3762
Meifang ZhouDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0009-0007-2095-4337
Chaoqun NieDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0003-2405-1913
Mengyuan ZhuDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Sijie ChengDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Tianyi WangDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Jing WangDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0002-0937-6456
Zhen QuanDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Kaiqi WangDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Shanshan LiuDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0009-0000-1792-2026
Xinxin HuDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Haoyu WangDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Jiannan WangDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Yongyi WuDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.
Xilin SunDepartment of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0003-0453-4862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The currently available immune checkpoint inhibitors (ICIs) often fail to achieve the desired clinical outcomes due to inadequate immune activation, particularly in patients with lung cancer. To reverse this situation, we synthesized inhalable PFCE-C25 nanoemulsions (NEs), which target lymphocyte activation genes (LAG-3) on immune cells within tumor microenvironment and tumor-draining lymph nodes (TDLNs). By combining in vivo

Indexed as

Lung NeoplasmsAdministration, InhalationAnimalsCell Line, TumorDendritic CellsDisease Models, AnimalEmulsionsHumansLymph NodesLymphocyte Activation Gene 3 ProteinMiceNanoparticlesTumor MicroenvironmentEmulsionsLymphocyte Activation Gene 3 Protein

Identifiers

PMID39612330
PMCPMC11606447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.